TARSONS NSE filing

Tarsons Products Q2 FY27 Revenue Grows 21% YoY to ₹123.7 Cr; PAT Declines

The RealCase readMedium impact Neutral

Tarsons Products reported consolidated revenue of ₹123.7 Cr for Q2 FY27, up 21% YoY. Standalone revenue rose 25% to ₹100.2 Cr. Exports grew 37% in Q2. However, consolidated PAT turned negative at ₹0.3 Cr for Q2 FY27 due to higher costs and depreciation from new facilities. Cash PAT grew 8%.

Why it matters

The strong revenue growth indicates positive business momentum. However, the decline in profitability and the reasons cited (increased costs, depreciation from new facilities) temper the positive outlook, suggesting a moderate impact on investor sentiment and future performance expectations.

The market read

The company reported strong revenue growth, which is positive. However, the PAT turned negative for the quarter and half-year due to increased costs and depreciation, which is a negative factor. The neutral sentiment reflects this mixed performance.

Tarsons Products Limited announced its financial results for the quarter and half-year ended September 30, 2026. The company reported a consolidated revenue of ₹123.7 crore for Q2 FY27, marking a 21% year-on-year increase. For the half-year ended September 30, 2027 (H1 FY27), consolidated revenue grew by 21% to ₹233.9 crore.

Standalone revenue for Q2 FY27 increased by 25% to ₹100.2 crore, and for H1 FY27, it grew by 23% to ₹186.4 crore. The domestic business showed robust growth of 19% in Q2 and 18% in H1 FY27, supported by demand in healthcare and pharmaceuticals. Exports also demonstrated strong recovery with 37% and 33% YoY growth in Q2 and H1 FY27, respectively. The Nerbe business reported steady performance with 7% and 13% revenue growth in Q2 and H1 FY27.

However, consolidated Profit After Tax (PAT) for Q2 FY27 declined to a loss of ₹0.3 crore compared to a profit of ₹3.3 crore in Q2 FY26. For H1 FY27, consolidated PAT was a loss of ₹1.8 crore, down from a profit of ₹5.1 crore in H1 FY26. This decline in PAT was attributed to accelerated depreciation and higher finance costs associated with the new Amta and Panchla facilities, which are expected to contribute meaningfully from FY28 onwards. Margins were impacted by an increase in raw material prices due to supply chain disruptions and geopolitical challenges.

Despite the challenges, Cash PAT for consolidated operations grew by 8% in Q2 FY27 and 13% in H1 FY27. The company highlighted investments in new capacities at Amta and Panchla, with cell culture lines at Panchla expected to become operational in H2 FY27. Management expressed confidence in sustained demand momentum and a positive growth trajectory, supported by an expanded product portfolio and enhanced manufacturing capabilities.

Filing to action

What to do with a filing like this

Tarsons Products Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Tarsons Products Limited. Read the original for the full detail.

View original filing